Prices as of 2026/10/30 close
Company comparison · Major Pharmaceuticals
Takeda is the bigger company, with revenue of ¥4.5T — 2.1x Daiichi Sankyo's ¥2.1T.
Daiichi Sankyo earns more on each yen of sales, with an operating margin of 10.8% — 1.7 points above Takeda (9.1%).
Revenue growth in the latest results: Daiichi Sankyo +12.6%, Takeda −1.7%. For next year, Daiichi Sankyo guides for the fastest operating profit growth (+37.5%).
Takeda pays more on average — ¥11.0M against ¥11.0M at Daiichi Sankyo.
Over the past year the shares moved Takeda +57.1%, Daiichi Sankyo −28.7%.
Head-to-head wins16 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Takeda aheadTakeda 2 : Daiichi Sankyo 1
Revenue: Takeda ¥4.5T / Daiichi Sankyo ¥2.1T
ProfitabilityInvestors
Daiichi Sankyo aheadTakeda 1 : Daiichi Sankyo 2
Operating margin: Takeda 9.1% / Daiichi Sankyo 10.8%
GrowthInvestors
Daiichi Sankyo aheadTakeda 1 : Daiichi Sankyo 4
Revenue growth (YoY): Takeda −1.7% / Daiichi Sankyo +12.6%
Stock & balance sheetInvestors
Takeda aheadTakeda 2 : Daiichi Sankyo 0
Share price, 1 year: Takeda +57.1% / Daiichi Sankyo −28.7%
Pay & workforceJob seekers
Daiichi Sankyo aheadTakeda 1 : Daiichi Sankyo 2
Average salary: Takeda ¥11.0M / Daiichi Sankyo ¥11.0M
| Metric | Takeda | Daiichi Sankyo | Gap |
|---|---|---|---|
| Revenue | ◎¥4.5T | ¥2.1T | 2.1x |
| Operating profit | ◎¥408.8B | ¥229.1B | 1.8x |
| Net income | ¥191.8B | ◎¥259.9B | 1.4x |
| Metric | Takeda | Daiichi Sankyo | Gap |
|---|---|---|---|
| Operating margin | 9.1% | ◎10.8% | 1.7pt |
| Net margin | 4.3% | ◎12.2% | 8.0pt |
| Revenue per employee | ◎¥937M | ¥265M | 3.5x |
| Metric | Takeda | Daiichi Sankyo | Gap |
|---|---|---|---|
| Revenue growth (YoY) | −1.7% | ◎+12.6% | 14.3pt |
| Operating profit growth (YoY) | ◎+19.3% | −31.0% | 50.3pt |
| Revenue CAGRlast 5 years | +7.1% | ◎+17.1% | 10.0pt |
| Guidance: revenue growthnext FY plan | +3.0% | ◎+7.4% | 4.4pt |
| Guidance: op. profit growthnext FY plan | +2.7% | ◎+37.5% | 34.8pt |
| Metric | Takeda | Daiichi Sankyo | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+57.1% | −28.7% | 85.8pt |
| Share price, 3 months | ◎+16.3% | −4.7% | 21.0pt |
| Share price (close) | ¥6,651 | ¥2,754 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Takeda | Daiichi Sankyo | Gap |
|---|---|---|---|
| Average salary | ◎¥11.0M | ¥11.0M | ¥0.06M |
| Starting salary (monthly) | ¥300,000 | ◎¥360,500 | ¥60,500 |
| Average tenure | 14.4 yrs | ◎19.9 yrs | 5.5 |
| Average age | 43.4 | 45.0 | 1.6 |
| Employees | 4,808 | 8,009 | 1.7x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥6,651+57.1% (1Y)
Takeda +57.1% over 1Y. Compared: Daiichi Sankyo -28.7%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Takeda5 segments
Daiichi Sankyo3 segments
AAverage annual salary from the securities filings: Takeda ¥11.0M, Daiichi Sankyo ¥11.0M. Takeda pays the most. Averages also depend on staff age and job mix, so check the average age too (Takeda 43.4, Daiichi Sankyo 45.0).
ARevenue in the latest results: Takeda ¥4.5T, Daiichi Sankyo ¥2.1T. Takeda is the bigger company, with revenue of ¥4.5T — 2.1x Daiichi Sankyo's ¥2.1T.
AOperating margins: Daiichi Sankyo 10.8%, Takeda 9.1%. Daiichi Sankyo turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Takeda +57.1%, Daiichi Sankyo −28.7%. Takeda has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
